Microbot Medical (MBOT) has issued an update.
Microbot Medical Inc. has successfully completed the inaugural patient procedure with its LIBERTY® Endovascular Robotic Surgical System at Brigham and Women’s Hospital, marking a significant step in their clinical trial for the innovative device. This milestone is expected to bolster their efforts for FDA submission and future market release. The company’s forward-looking statements indicate a positive outlook on achieving regulatory goals but also acknowledge potential variations in future results.
Find detailed analytics on MBOT stock on TipRanks’ Stock Analysis page.
